Results 81 to 90 of about 2,221,794 (256)
The exposition of α1-acid glycoprotein and fibronectin on the surface and inside the lymphocytes of healthy donors and hematological patients with acute and chronic myeloid leukemia were studied.
G. S. Маslak
doaj +1 more source
Cancer treatment is associated with measurable acceleration of biological aging across epigenetic, telomere, senescence, and immune biomarkers. However, biomarker validation and interventional strategies remain limited, especially in hematologic malignancies, underscoring the need for standardized multi‐omic aging assessments and adequately powered ...
Moataz Ellithi +3 more
wiley +1 more source
Prenatal origin of childhood AML occurs less frequently than in childhood ALL [PDF]
Background While there is enough convincing evidence in childhood acute lymphoblastic leukemia (ALL), the data on the pre-natal origin in childhood acute myeloid leukemia (AML) are less comprehensive.
Meyer, Claus +31 more
core +2 more sources
Background Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in success rate and/or ...
Brian V. Balgobind +19 more
doaj +1 more source
Mineralization alone does not establish a mature bone organoid. This Review integrates biological foundations, materials design, adaptive remodeling, and translational validation through the development‐to‐remodeling continuum (DRC). By separating biological functions from the evidence supporting them, the framework exposes critical gaps in current ...
Xijie Tang +4 more
wiley +1 more source
Monitoring of minimal residual disease in acute myeloid leukemia
Deep insight on Monitoring of minimal residual disease in acute myeloid ...
Schnittger, S +3 more
core +1 more source
Non‐acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17)
Key Clinical Message t(11;17) is a rare but recognized finding usually found in Acute Promyelocytic Leukemia with variant RARA translocation (APLv). We present a case of Acute Myeloid Leukemia with t(11;17) that has different break points than those ...
Rahaf Altahan +2 more
doaj +1 more source
Background Until recently, few molecular aberrations were recognized in acute lymphoblastic leukemia of T-cell origin; novel lesions have recently been identified and a certain degree of overlap between acute myeloid leukemia and T-cell acute ...
Sabina Chiaretti +14 more
doaj +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Therapy of Acute Myeloid Leukemia
The Eastern Cooperative Oncology Group (ECOG) has recently reviewed the outcome for more than 1,400 patients with previously untreated AML entered on five successive clinical trials.5,6 Each trial included daunorubicin and cytarabine for induction.
openaire +2 more sources

